Skye Bioscience, Inc.
SKYEDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SKYE Earnings Report
EPS Est: $-0.29 | FQ end 2026-06
How SKYE's past catalysts played out
Nimacimab injection
Obesity
SBI-100 Ophthalmic Emulsion, 0.5%
Primary Open Angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nimacimab injection | Phase 2 | Obesity | - | - |
SBI-100 Ophthalmic Emulsion, 0.5% | Phase 2 | Primary Open Angle Glaucoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Skye Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Skye Bioscience, Inc.'s (SKYE) pipeline across Phase 2. Its lead program is Nimacimab injection (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Skye Bioscience, Inc.'s next FDA catalyst?→
Skye Bioscience, Inc.'s (SKYE) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SKYE biotech catalysts?→
Add SKYE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Skye Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.